Articles tagged with Drug Candidates
Researchers have discovered a new way to identify and test new drugs using differential mobility spectrometry (DMS), which analyzes drug molecules based on their response to an electrical field. This technique can measure drug properties in seconds, allowing for high-throughput testing of hundreds or thousands of drugs.
Researchers have identified B0AT1 inhibitors as a potential replacement for gastric bypass surgery in treating obesity and related disorders. These compounds, including benztropine, could replicate the effects of gastric bypass by reducing nutrient absorption, offering a new treatment option.
A breakthrough study by Dr. Xinglong Wang has linked ALS and dementias to TDP-43 toxicity in mitochondria, offering new hope for treatment. His team discovered a small-molecule peptide that can reverse symptoms of ALS in mice, paving the way for potential therapeutic approaches.
Researchers discover over 31,000 repurposable drug candidates for various diseases, including Parkinson's and tuberculosis. The study uses computational methods to identify shared properties between genes, drugs, and diseases, promising a more efficient and cost-effective approach to pharmaceutical discoveries.
Researchers from Duke University have identified two specific receptors, CXCR2 and LTBR, that play a key role in the development of drug-resistant multiple sclerosis. The study found that targeting these receptors may lead to successful treatment for patients who do not respond to interferon-beta treatment.
A new study suggests a dual-targeting drug candidate could treat both type 2 diabetes and bone disease by expanding bone formation and turnover. The compound has shown promise in increasing bone mass regardless of body mass index.
Researchers identified a new drug target, BRD9, in acute myeloid leukemia and developed a candidate drug, BI-7273. The team discovered that replacing the native bromodomain with a functionally synonymous one allowed them to prove how the drug works, providing valuable information for drug development.
Researchers found that a plant-virus-based carrier successfully delivers the drug candidate phenanthriplatin, outperforming cisplatin in mouse models of triple-negative breast cancer. The nanoparticles target tumors, accumulating inside lysosomal compartments and releasing the drug to block transcription, leading to greater cell death.
Researchers have created a drug candidate that targets and neutralizes the RNA structure causing an incurable progressive disease, spinocerebellar ataxia type 10. The compound, 2AU-2, improves several aspects of cells taken from patients with SCA10, offering new hope for treating dozens of incurable diseases.
Scientists at Scripps Research Institute designed a drug candidate that targets cancer-causing RNA, eliminating side effects and reducing tumor growth. The study demonstrates a clear breakthrough in precision medicine, using computational approaches to develop designer compounds.
Scientists at Scripps Research Institute have identified a novel drug candidate that targets serine biosynthesis in cancer cells, inhibiting their growth. The new compound, CBR-5884, specifically targets the enzyme PHGDH, which is responsible for serine production, and shows promise in treating breast cancer, lung cancer, and melanoma.
A spider toxin analogue, PnPP-19, has shown promise in relieving pain by targeting nervous system receptors similar to opioids and cannabis. The compound is also being studied for erectile dysfunction treatment.
Lawrence Livermore National Laboratory researchers developed a simulation to predict the permeability of drug molecules across cell membranes, enabling faster testing and development of nerve-agent treatments. The simulation shaved weeks off compound testing, reducing the time required from six weeks to just 16 hours.
Researchers developed a family of reagents to add ring-shaped structures to drug candidates, reducing multiple steps in synthesis. This innovation may help speed up the development process for numerous pharmaceuticals.
The Phase I study confirms the therapeutic dose and safety profile of SCYX-7158, a first oral drug candidate specifically developed to combat human African trypanosomiasis. The study results translate into prolonged exposure with just one dose, targeting the late stage of the disease where the parasite crosses the blood-brain barrier.
Researchers at Scripps Research Institute have received a nearly $4.5 million grant with the possibility of up to $10 million to complete preclinical studies on a new anti-migraine drug candidate. The compound has shown promising results in treating stress-induced migraine and may be developed into a once-a-day pill.
Researchers at Johns Hopkins Medicine have developed a high-throughput screening technique using zebrafish embryos to identify 24 potential new diabetes drugs. The novel method may also be applied to other diseases, including heart disease and neurodegenerative conditions.
Scientists at Scripps Research Institute have discovered a bacterial enzyme that can degrade nicotine, offering a potential alternative to smoking cessation aids. The enzyme, NicA2 from Pseudomonas putida, has shown promising characteristics for drug development, including stability in lab settings and minimal toxic byproducts.
Researchers at Scripps Florida will study RORs, molecules that regulate circadian rhythm and carbohydrate metabolism, to better understand their role in neurological disorders. The new grant aims to expand the understanding of these receptors and develop experimental compounds for treating conditions like depression and bipolar disease.
A new algorithm, DeMAND, is helping scientists identify the full repertoire of proteins affected by a drug. By analyzing gene expression changes and protein interactions, DeMAND provides a more comprehensive picture of a drug's effects.
EPFL scientists identified lansoprazole as an excellent candidate against tuberculosis, a global pandemic, by screening thousands of approved drugs. The study found that lansoprazole kills the bacterium after being converted into a sulfur-containing metabolite, targeting a crucial enzyme for energy production.
Scientists from Scripps Research Institute aim to develop drugs targeting the IP6K1 enzyme to treat obesity and related metabolic diseases. The new grant will help identify underlying mechanisms of energy storage regulation.
Researchers have discovered a promising new treatment for Ebola by screening compounds from existing malaria and flu drugs. The treatment showed a high success rate of up to 90% in treating infected mice with no observable side effects.
Revolution Medicines has developed a unified 'building blocks' approach for synthesizing multiple classes of complex natural chemicals that could be valuable backbones for new medicines. The company's technology can produce a broad range of molecules, including those with diverse types of chemical bonds and highly complex cyclic struct...
DeuteRx has discovered a method for in vivo stabilization and differentiation of thalidomide analogs, improving anti-inflammatory and antitumorigenic properties. The company's 'deuterium-enabled chiral switching' platform enables the testing and development of single enantiomers with improved therapeutic properties.
Researchers from Scripps Florida have developed an anti-HIV agent that blocks all strains of HIV-1, HIV-2, and SIV, offering potential protection for at least eight months after injection. The new compound binds to the virus's envelope, preventing entry into host cells.
Dartmouth investigators develop new algorithms that employ molecular modeling to optimize deimmunized drug candidates. The approach resulted in highly-active and stable biotherapeutic designs that addressed immunogenic hotspots not easily targeted by earlier methods.
Researchers at Scripps Research Institute have identified drug candidates targeting biological pathways involved in brain cell destruction in Parkinson's disease. The new compounds selectively inhibit JNK kinases, which play a central role in the disease, and show promise as potential therapeutics.
A new drug candidate called DBIBB increases the survival of mice suffering from radiation syndrome, even when treatment was delayed by three days. The compound protects against DNA damage and enhances the survival of various types of cells, showing promise for treating acute radiation syndrome.
Scientists developed a new compound that targets the 'receptor' responsible for pain caused by chili peppers. The compound, tested in clinical trials, has shown promise in treating various types of pain.
Researchers at Uppsala University discovered that Upsalite, a highly porous magnesium carbonate, can improve the solubility and bioavailability of poorly soluble drugs. By using Upsalite, about 40% of newly marketed drugs with poor solubility may have their therapeutic efficacy enhanced.
A drug candidate developed to treat sickle cell disease has been acquired by Baxter International, advancing its clinical development activities. Aes-103 significantly reduces patients' pain in Phase II clinical trials, offering a potential breakthrough treatment.
A new transdermal selective androgen receptor modulator (SARM) drug may help older cancer patients build muscle without harming liver function or HDL levels. The novel compound, AUSRM-057, avoids negative impacts on prostate health, making it a promising treatment option.
Pharmacists at Jena University have developed three potential therapeutic agents that may improve the healing of inflammatory illnesses. The agents suppress a key enzyme in the body's own cascade of inflammation, specifically targeting 5-LOX, which plays a pivotal role in synthesizing leukotrienes. This breakthrough could lead to more ...
A new study identifies three potential drug candidates for treating autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and psoriasis. The researchers used genome analysis to target a specific molecule within immune cells that drives these diseases.
Researchers have developed a new technique for making unnatural amino acids, which are sought after by the pharmaceutical industry for their medical uses. The method employs special ligand compounds to enhance the ability of a palladium catalyst to break carbon-hydrogen bonds.
Researchers at Scripps Research Institute create Inforna, a technique to identify potent compounds targeting cancer-causing microRNAs. The method enables unprecedented targeting of disease-associated RNAs, offering a promising approach to designing novel anti-cancer drugs.
Researchers at VIB have identified a chemical substance that can disarm pathogenic bacteria, allowing them to treat urinary tract infections without destroying beneficial bacteria. This approach could provide a lower risk of resistance development and spread.
Researchers at Scripps Research Institute describe two new drug scaffolds that target the kappa opioid receptor, offering novel tools for treating pain, addiction, and other disorders. The compounds, called biased agonists, activate the receptor without recruiting beta arrestin, a molecule associated with depression.
A new study published in Blood journal presents a Swedish cancer drug candidate that inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The substance also kills multiple myeloma cells from cancer patients and overcomes resistance to clinically used drugs.
Wayne State University has licensed an intellectual property portfolio claiming composition of matter and methods of use of novel analogs and derivatives of the green tea flavonoid EGCG. The collaboration, involving Q. Ping Dou and Tak-Hang Chan, aims to develop novel approaches for cancer management and related conditions.
Researchers have identified a potential new drug for an inherited form of cancer with no known cure. The new compound, FRAX97, targets a protein family that plays a critical role in the development of Neurofibromatosis type 2. By inhibiting these kinases, tumor growth can be slowed and progression reduced by over 80%.
Scientists at Scripps Research Institute have developed a novel method to increase the potency of RNA treatments, resulting in a 2,500-fold improvement. The breakthrough enables precise targeting of disease-causing RNAs and could lead to more effective therapeutic agents.
Researchers at Karolinska Institutet developed a breakthrough method called CETSA to measure drug molecules' binding to target proteins. This enables more efficient development of new drugs and potential improvement in cancer treatments.
Researchers have rediscovered PARP inhibitors as potential treatments for BRCA-driven cancers, including ovarian and breast cancers. Four drug candidates are now set to enter Phase III clinical studies.
RG3039 demonstrates benefits in two SMA mouse models, extending survival and improving motor unit function. The drug also positively modifies motor unit pathologies and dysfunction, suggesting potential therapeutic benefit for SMA patients.
A synthetic compound ShK-186, derived from a sea anemone toxin, enhances metabolic activity and shows potential as a treatment for obesity. The compound selectively blocks the activity of a protein that promotes inflammation through the Kv1.3 potassium channel.
A new study offers promising hope for treating progeria by targeting the enzyme ICMT, which causes premature aging. Researchers have successfully tested an ICMT inhibitor on mice, reducing or blocking the development of progeria symptoms and increasing cell growth.
Scientists from VIB and KU Leuven discovered a new target molecule to develop a treatment against Alzheimer's disease. β-arrestin 2 plays a role in regulating the γ-secretase complex function and development of the disease. This research opens a new avenue for treating the disease at an early stage.
A new genetic sequencing tool, Next-Gen Lab-on-Bead, has been developed to speed up drug discovery and disease diagnostics. The technology uses next-generation sequencing to test millions of potential drug candidates simultaneously.
Researchers developed a medicated chewing gum formulation that improves patient compliance and faster absorption through the cheek, alleviating motion sickness sooner. Dimenhydrinate-based gum has great potential for commercialization and can be used to incorporate other active ingredients with objectionable taste into chewing gum.
Researchers at Washington State University have developed a new drug candidate that improves cognitive function in rats with Alzheimer's-like mental impairment by building new brain cell connections. The compound, called Dihexa, is stable and can cross the blood-brain barrier, allowing for pill-form administration.
Researchers found pyridomycin selectively kills Mycobacterium tuberculosis, including strains resistant to front-line drug isoniazid. The natural antibiotic targets the InhA enzyme, which is essential for bacterial cell wall production.
Christina Smolke, a Stanford bioengineer, has won a $2.5 million grant to explore using microbes to produce complex chemicals for advanced natural-product drugs. Her approach aims to transform the manufacturing scale and efficiency of microbial systems.
A novel approach to discover the first new tuberculosis (TB) combination drug regimen has cleared a major hurdle with a Phase II clinical trial finding it could kill more than 99 percent of patients' TB bacteria within two weeks. The results add to a growing body of evidence that this regimen could reduce treatment by more than a year ...
A new drug candidate, K11777, has shown promising results in treating hookworm infections with a single oral dose. The compound is under development to enter clinical trials and could provide a new solution for treating the disease if it proves safe and effective in humans.
A cross-disciplinary team at the University of Maryland has designed molecular containers that can hold drug molecules and increase their solubility up to nearly 3000 times. The discovery opens possibilities for rehabilitating drug candidates and improving successful drugs with better solubility.
Researchers from Notre Dame's Eck Institute for Global Health have developed a novel method using a gene chip to identify malaria drug resistance. This technology enables real-time response and modification of treatment strategies to combat emerging resistance.
The Wistar Institute is developing a new drug to treat Epstein-Barr virus-related cancers by targeting the dormant EBV virus in patient cells. The project aims to create a viable drug candidate with potential to save countless lives globally.
Scientists have identified small-molecule drug candidates that activate the TMEM16A channel, promoting salt and water movement in cells. The discovery could lead to new therapies for conditions such as cystic fibrosis, dry eye, and slow-transit constipation.